Introduction {#Sec1}
============

Treatment compliance, defined as the extent to which a patient acts in accordance with the prescribed interval and dose as well as dosing regimen, is a key factor in the management of bone health, in the same way as in other chronic diseases \[[@CR1]\]. Patient compliance improves effectiveness of osteoporosis treatment. When patients comply, there is a rise of bone mineral density, reduction of fracture risk, and improved quality of life \[[@CR1], [@CR2]\]. Unfortunately, long-term compliance with treatment has been shown to be poor in osteoporosis and about half of patients stop therapy within 1 to 2 years \[[@CR3]\]. Compliance could even be lower with supplementation with calcium and/or vitamin D \[[@CR4]\]. For example, it has been suggested, in a multicentre study conducted in Spain, that only two in ten patients effectively comply with calcium and vitamin D treatment after 1 year or more of its prescription \[[@CR5]\].

However, calcium and vitamin D are essential for the maintenance of bone homeostasis. Most of the current guidelines recommend a daily intake of calcium in postmenopausal women of at least 1000 to 1200 mg, together with at least 800 IU of vitamin D \[[@CR6], [@CR7]\]. Besides its effect on falls and fractures, results from ecological, case-control and cohort studies have also shown that high vitamin D levels were associated with reduced risks of autoimmune diseases, type 2 diabetes, cardiovascular diseases and cancers \[[@CR8]\]. Unfortunately, vitamin D status of the general population is largely below the recommended level. Indeed, it is estimated that one billion people worldwide have vitamin D deficiency or insufficiency \[[@CR9]\].

Regarding calcium, the needs for adults are generally recognized as the intake required to maintain calcium balance and therefore skeletal integrity \[[@CR10]\]. The Recommended Dietary Allowance (RDA) for European adults is 800 mg/day. After menopause, the calcium requirements increase to at least 1000 mg/day \[[@CR11]\]. Most of the epidemiological studies suggest that calcium intake in this population is below the recommendations \[[@CR12], [@CR13]\].

Recent data suggest that there is an increased risk of incident myocardial infarction in patients taking calcium \[[@CR14]--[@CR16]\]. However, other studies or critical reviews of the literature by other groups of researchers do not support this finding \[[@CR17]--[@CR22]\]. As a consequence, the safety of calcium supplements has drawn much controversy, especially since its use is becoming more prevalent \[[@CR23]\]. Obviously, this could also have an impact on compliance with calcium supplementation.

Another factor impacting compliance with treatment is the frequency of treatment administration \[[@CR1]\]. In the field of bone health, pharmacological interventions, including vitamin D supplementation, have been developed with daily, weekly, monthly or multiannually regimes with the objective to improve compliance. This is particularly sensible with vitamin D because such an approach offers a realistic and pragmatic public health measure to target at-risk populations and addresses the emerging public health issue of widespread vitamin D insufficiency. However, still with vitamin D, dosing intervals of more than 2--3 months and/or intermittent bolus doses (200,000 IU) are not regarded as physiological and could affect clinical outcomes because of a difference in the bioavailability of vitamin D \[[@CR24], [@CR25]\]. The question of the ideal time between doses is, however, still of debate.

The aims of the present study are to compare the compliance with a once-monthly administration of vitamin D3 to compliance with a daily administration of a fixed-dose combination of vitamin D3 and calcium during two 6-month periods and to assess their effect on the level of vitamin D.

Material and methods {#Sec2}
====================

Study design {#Sec3}
------------

This was a phase IV, two-armed, randomized, open, cross-over study conducted in adult volunteers aged 50 years old or older. One hundred (100) volunteers were randomized from a single investigational site in Belgium in only 4 months (October 2012--February 2013). After the screening visit (month 0), volunteers respecting all inclusion/exclusion criteria were divided into two groups of treatment. One hundred volunteers were randomized to receive either one drinkable ampoule containing 25,000 IU vitamin D3 once monthly (i.e. group VD) or one chewable tablet containing 1000 mg calcium carbonate + 800 IU vitamin D3 once daily (i.e. group VDCa) during 6 months. After the first 6 months of treatment, the groups were reversed and each volunteer received the other treatment for another period of 6 months according to the cross-over design. Volunteers were asked to come to the investigator site for three visits, during the study period: month 0, month 6 and month 12.

Subjects {#Sec4}
--------

Male and female subjects 50 years old or older with a body mass index (BMI) between 18 and 35 kg/m^2^ were included in this study. Volunteers who met any of the following criteria were excluded from participating in the study: use of drugs which may interfere with vitamin D metabolism (e.g. phenobarbital, phenytoin and oral and parenteral glucocorticoids), use of any vitamin D supplement alone or in association (i.e. multivitamin, vitamin D/calcium combination or vitamin D/biphosphonate combination) within 4 weeks before the screening visit; UV light solarium was used 2 weeks before the screening visit and during the study.

All subjects provided written, informed consent to participate in the study, indicated by a personal signature and date on the volunteer consent form.

Assessments {#Sec5}
-----------

At screening (T0), demographics, medical history, previous and concomitant medications, and vitamin D status were all evaluated. Moreover, instructions for drug administration were given. After 6 months, concomitant medications, adverse events, compliance, persistence, treatment acceptability and vitamin D status were also evaluated. At the end of the study (T12), concomitant medications, compliance, persistence, adverse events and treatment acceptability were again evaluated. A questionnaire about the preferred treatment was also submitted to the patients.

The following procedures were observed:Treatment compliance (i.e. the primary outcome): calculated as the number of tablets/ampoules taken by the patient divided by the number of tablets/ampoules to be taken for a given period of timeVitamin D status: the level of 25(OH)D level was assessed with the DiaSorin Liaison assay (Saluggia, Italy). In our procedure, the CV was \<8 %.Treatment preference: a questionnaire assessing the possible preference of the subject for one of the treatments was given to all subjects. The reason, including taste, ease of use, frequency of use, number of adverse events, reputation of the treatment, was also asked.Treatment acceptability: overall satisfaction was assessed by a questionnaire. More specific questions on taste, ease of use, frequency of use and occurrence of adverse events were also asked.Adverse events (AEs): the number of events, but also the number of patients, with emergent AEs, treatment-related AEs, severe AEs, severe and treatment-related AEs, serious AEs (SAEs), treatment-related SAEs, withdrawals due to AEs and withdrawals due to treatment-related AEs were reported.

Statistical analysis {#Sec6}
--------------------

The Shapiro-Wilk test was utilized to test if population distribution was normally distributed or not. Quantitative variables were expressed by mean, standard deviation (SD) or median and interquartile range (P25--P75) for asymmetric distributions. Qualitative variables were expressed by number and percentage. For quantitative variables, comparison between the two groups of treatment was assessed by means of a Student *t* test for independent populations or a non-parametric Mann-Whitney test if normality was not satisfied. The relationship between qualitative variables and group of treatment was assessed using a chi^2^ test. As the study design was a cross-over study, compliance was analyzed according to the method described in D. G. Altman ("Statistical methods for medical research", Chapman and Hall, London, 1991). This method consists of testing a period/sequence effect, then an interaction effect between period and treatment, and finally, and only in case of no significant effect of period and interaction, a treatment effect. All effects are assessed by using a two-sample *t* test or a non-parametric test of Mann-Whitney. To test the mean evolution of vitamin D between T0 and T6 within the two treatment groups, a Student *t* test for independent samples was used. The relationship between the main reasons of preference to a treatment and the chosen treatment was assessed by a Fisher exact test. For each criterion of acceptability (taste, ease of use, frequency of use, AEs and overall satisfaction), the categories 'not at all satisfied', 'slightly satisfied' and 'moderately satisfied' were regrouped due to few data. For the same reason, the categories 'very much satisfied' and 'extremely satisfied' were also regrouped. For each acceptability criterion, the degree of satisfaction for the two treatments was compared by means a McNemar test. Results were considered to be statistically significant at the 5 % critical level (*p* \< 0.05). Data analysis was carried out using SAS (version 9.3 for Windows) and R (version 2.15) statistical packages.

Results {#Sec7}
=======

The first patient was randomized on October 15, 2012. A total of 100 patients were enrolled over 4 months (last randomization date February 14, 2013). The last visit took place on February 17, 2014.

At baseline (T0), no significant differences were found in any of the characteristics between the two groups of patients (Table [1](#Tab1){ref-type="table"}).Table 1Baseline characteristics for the two groups of treatmentVariableGroup 1 (*n* = 50)Group 2 (*n* = 49)*p* valueAge (years)65.5 (57.4--72.7)67.5 (61.2--73.8)0.38Median (P25--P75)Weight (kg)69.8 ± 12.372.2 ± 12.30.34Mean ± SDHeight (cm)160.9 ± 7.77164.2 ± 8.730.054BMI (kg/m^2^)26.9 ± 4.1026.7 ± 3.760.8225OHD (ng/mL)29.7 ± 11.227.6 ± 10.10.34Gender Male14 (28.0)13 (26.5)0.87 Female36 (72.0)36 (73.5)

For the two periods, the compliance was higher in the VD group than in the VDCa group (*p* \< 0.0001), and the greatest difference in compliance rate was observed for patients who changed from the VDCa group to the VD group. In both periods 1 and 2, the compliance in the VD group was 100 % (P25--P75 100--100) but was 96.2 % (83.1--100) and 91.7 % (76.9--96.8) for the VDCa group, in periods 1 and 2, respectively.

During the study, 50 (56.8 %) patients preferred the VD treatment, 16 (18.2 %) patients preferred the VDCa treatment and, for 22 (25.0 %) patients, neither treatment was preferred. Interestingly, the treatments were chosen for different reasons (*p* = 0.030, Table [2](#Tab2){ref-type="table"}). The main reason given by patients who preferred the VD treatment was the frequency of use (42 %), while VDCa was mainly chosen for its ease of use (62.4 %).Table 2Association between chosen reasons of preference and chosen treatmentVD groupVDCa groupFisher exact test*N* (%)*N* (%)*p*ReasonTaste2 (3.0)3 (18.8)0.030Ease of use17 (34.0)10 (62.4)Frequency of use21 (42.0)3 (18.8)No adverse events7 (14.0)0 (0.0)Treatment reputation0 (0.0)0 (0.0)Other3 (6.0)0 (0.)Total50 (76.5)16 (23.5)

Proportions of patients who were 'not at all satisfied' to 'moderately satisfied' were different depending on the treatment for the following acceptability criteria: (1) frequency of use (*p* = 0.0023) and (2) adverse events (*p* = 0.0010), patients being less satisfied when taking VDCa treatment. No difference was found for taste and ease of use criteria. When acceptability criteria were considered as continuous variables, satisfaction was higher with VD treatment for the following acceptability criteria: (1) frequency of use (*p* = 0.010), (2) adverse events (*p* = 0.0034) and (3) overall satisfaction (*p* \< 0.0001) (Table [3](#Tab3){ref-type="table"}).Table 3Association between acceptability criteria considered as continuous variables and treatmentAcceptabilityVD group (*n* = 87)VDCa group (*n* = 87)Non-parametric *p*Mean ± SDM (P25--P75)Mean ± SDM (P25--P75)Taste3.59 ± 0.974 (3--4)3.69 ± 0.894 (3--4)0.46Ease of use4.06 ± 0.644 (4--4)4.06 ± 0.704 (4--4)0.95Frequency of use4.06 ± 0.574 (4--4)3.77 ± 0.834 (3--4)0.010Adverse events4.24 ± 0.634 (4--5)3.90 ± 1.064 (4--5)0.0034Overall satisfaction2.91 ± 0.293 (3--3)2.63 ± 0.653 (2--3)\<0.0001

During the first 6 months of follow-up, the mean (SD) 25(OH)D increased from 29.1 ng/mL (10.9) to 35.7 ng/mL (8.85) in the VD group and from 27.9 ng/mL (10.2) to 31.8 ng/mL (8.8) in the VDCa group, without any statistical differences between groups (*p* = 0.16).

The incidence of adverse events related to treatment was low but more frequently reported by subjects on VDCa (Table [4](#Tab4){ref-type="table"}).These adverse events related to treatment were gastrointestinal disorders (i.e. constipation, nausea and abdominal upper pain).Table 4Summary table of adverse events for the safety populationVD groupVDCa group FORTE*N* (%) of patientsN of events*N* (%) of patient*N* of eventsEmergent AEs54 (54.5)10258 (58.6)107Treatment-related AEs4 (4.04)1010 (10.1)11Serious AEs6 (6.06)86 (6.06)7Treatment-related serious AEs0000Withdrawals due to AEs1(1.01)13 (3.03)3Withdrawals due to treatment-related AEs002 (2.02)2

Discussion {#Sec8}
==========

Strategies to improve patient compliance are of primary importance. Many interventions, involving different factors, may be considered. Indeed, there is evidence to support that a multifaceted strategy targeting cognitive, behavioural and emotional factors is more effective than one aimed at a single factor \[[@CR26]\]. Preference of the patients also needs to be taken into account \[[@CR27]\]. Indeed, besides the potential effect on compliance with treatment, the patient's perspective is becoming increasingly important in clinical and policy decisions. In our study, more patients preferred D-Cure®, but the two treatments (i.e. D-Cure® and Steovit Forte®) were chosen for different reasons. The frequency of use is the main reason given for choosing vitamin D alone, but it should be pointed that the potential reasons for preference were predefined.

Interestingly, increasing time between two doses has also been suggested to improve compliance. However, and more globally, the dose interval is still a matter of debate. On one side, some studies have suggested that compliance with monthly regimes could be better than with daily regimes \[[@CR1]\]. On the other side, according to a recent review, it is likely that for the optimal functioning of the endocrine/autocrine system, significant 25OHD should be available on a daily basis to ensure stable circulating concentrations, implying that variation in vitamin D dosing schedules could have profound effects on the outcomes of clinical trials because of the short circulating half-life of intact vitamin D \[[@CR24]\]. Consequently, the balance between bioavailability and compliance needs to be taken into account.

Anyway, it should be pointed out that although the exact consequences of dose interval on bone health outcome are not well known, the effect of the frequency of vitamin D administration on vitamin D status has already been investigated. In our study, even if the monthly intake has improved the vitamin D status more than the daily intake, it does not reach statistical significance. Other studies have compared daily, weekly and monthly vitamin D supplementation. In one 4-month study of equivalent oral doses of vitamin D3 600 IU/day, 4200 IU/week and 18,000 IU/month, daily dosing was the most and monthly dosing the least effective to raise 25(OH)D concentrations \[[@CR28]\]. In another 2-month study, intakes of 1500 IU of D3 daily, 10,500 IU weekly and 45,000 IU once every 28 days were equally effective \[[@CR29]\]. In a 1-year study, intakes of 800 IU daily were more efficient than intakes of 97,333 IU every 4 months to increase serum 25(OH)D3 concentrations \[[@CR30]\]. Another study, conducted over a period of 3 months, showed no difference in the improvement of vitamin D status between supplementations of 2000 IU/day or 60,000 IU/month \[[@CR31]\].

It should also be noted that even if most of the epidemiological studies suggest that the prevalence of adequate calcium intake is low, the supplementation of calcium is not necessary in subjects with sufficient intake of calcium from food. Indeed, the best way to meet the daily dietary calcium requirement is through the intake of foods high in calcium: such as dairy products, green vegetables, and mineral waters \[[@CR10]\]. Dairy products may represent one of the best dietary sources of calcium as they provide more calcium (and protein, magnesium, potassium, zinc and phosphorus) per calorie than any other typical food found in the adult diet \[[@CR32]\]. The recommended consumption is three portions of dairy products per day (for example, one glass of milk, one portion of cheese and one yogurt). This amount could provide most of the calcium needs of the general population and could limit the use or the dose of calcium supplementation in the elderly. Another possibility to improve calcium intake, keeping a once-monthly intake of vitamin D, would be with food fortification. A variety of calcium-fortified foods, such as orange juice and soy milk, are available in some countries and provide the same amount of calcium as dairy products. Interestingly, it has been calculated, from the FINDIET data, that calcium fortification of only 11 % of all fortifiable foods would lead to a decrease of the proportion of participants with calcium intake below the recommended level from 20.3 to 15.7 % in men and from 27.8 to 23.2 % in women \[[@CR33]\].

We should acknowledge that besides the open-label design of this study, a major limitation of this study is that no daily calcium supplementation was given to the subjects from the monthly dose of the vitamin D group. Obviously, the well-known minor adverse events (e.g. gastrointestinal disorders) observed with calcium supplementation could have affected the compliance with the combined calcium/vitamin D product that, in turn, could have influenced the vitamin D status. However, because of the controversies regarding calcium supplementation, some prescribers and some patients could be willing to avoid such supplementation. In these circumstances, strategies to increase calcium intake through calcium-fortified food should be activated.

On the other side, in Belgium, where this study was conducted, there is no other supplement than D-Cure® containing cholecalciferol alone. All specialities containing cholecalciferol are combined with calcium. Steovit Forte® was chosen, as the dose of cholecalciferol (800 IU/daily) is the closest to that of D-Cure® (25.000 IU/month). It should then be pointed out that the monthly total dose of vitamin D3 delivered in the monthly supplement was 1000 IU greater than in the daily supplement. The cost per month is 1.25€ for D-Cure® and 15.87€ for Steovit Forte®. In our study, a substantial proportion of the volunteers were previously treated with D-Cure® and/or Steovit Forte®. Therefore, both products were well known by the volunteers before their entry in the study. In addition, both products are available on the Belgium market since many years and without prescription over the counter.

In conclusion, our study demonstrated that a monthly dose of vitamin D is preferred to a daily combined administration of calcium and vitamin D and leads to a better compliance but without a significant difference in serum vitamin D concentration between both regimes/treatments.
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